Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer currently includes six marketed products. Several other compounds are in various stages of clinical development, with the focus on potential first-in-class approaches across the areas of novel oncogenic signaling in combination with an effective biomarker strategy, antibody drug conjugates including a thorium platform and immuno-oncology. An Oncology Strategic Business Unit within the Pharmaceuticals Division of Bayer was established in 2017 to support the accelerated development of new treatment options. The company has also established a broad cooperative research network with healthcare professionals, academic research centers, other pharmaceutical companies and innovative biotech organizations worldwide. Together with these partners, we are fostering an open exchange of ideas to expand Bayer's vision of treatment for cancer patients.